Shares of ProMetic Life Sciences Inc. (TSE:PLI) have received a consensus rating of “Buy” from the six analysts that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is C$3.50.

A number of analysts have commented on PLI shares. National Bank Financial reduced their price target on ProMetic Life Sciences from C$2.50 to C$2.00 and set a “sector perform” rating for the company in a research report on Wednesday, November 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of ProMetic Life Sciences in a research report on Monday, November 20th.

In other news, insider Jonathan Booth purchased 75,000 shares of the stock in a transaction on Friday, October 6th. The stock was bought at an average price of C$1.21 per share, with a total value of C$90,750.00. In the last ninety days, insiders have acquired 85,625 shares of company stock valued at $107,475.

ProMetic Life Sciences (TSE:PLI) traded down C$0.03 during trading on Tuesday, reaching C$1.30. The company had a trading volume of 690,089 shares, compared to its average volume of 993,683. The stock has a market capitalization of $923.47, a PE ratio of -7.65 and a beta of 2.34. ProMetic Life Sciences has a 12 month low of C$1.12 and a 12 month high of C$2.64.

ILLEGAL ACTIVITY WARNING: This report was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/01/02/prometic-life-sciences-inc-pli-given-consensus-recommendation-of-buy-by-brokerages.html.

ProMetic Life Sciences Company Profile

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Analyst Recommendations for ProMetic Life Sciences (TSE:PLI)

Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.